In early 2015 Gebro Pharma breathed new air into the market by inaugurating a new therapeutic area: the respiratory area. The franchise opened its doors with a product that assisted patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). Tovanor® Breezhaler® arrived and began to tackle a disease that affects more than 10% of the population, and therefore has an enormous socio-health impact.
According to the WHO, the number of COPD patients is expected to rise in the coming decades, mainly due to continued exposure to risk factors, as well as aging and population growth.
The drug Tovanor® Breezhaler®, glycopyrronium bromide, is a maintenance bronchodilator treatment which aims to relieve the symptoms of adult patients with COPD.
At Gebro Pharma we are continuing to study new solutions to help us expand our range of products and provide more quality of life for patients with respiratory ailments.
1. SmPC Tovanor® Breezhaler®.
2. Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, Soriano JB, y Miravitlles M. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. International Journal of COPD 2018:13 57–6
3. Shireen Mirza, MBBS; Ryan D. Clay, MD; Matthew A. Koslow, MD; and Paul D. Scanlon, M. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc. 2018;93(10):1488-1502.